Spruce Biosciences (SPRB) Interest & Investment Income (2021 - 2026)
Spruce Biosciences (SPRB) posted quarterly Interest & Investment Income of $486000.0 for Q1 2026, up 47.72% year-over-year from $329000.0 in Q1 2025, and up 1315.0% quarter-over-quarter from -$40000.0 in Q4 2025.
Spruce Biosciences (SPRB) Interest & Investment Income (2021 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Interest & Investment Income for 6 consecutive years, with $486000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 47.72% year-over-year to $486000.0; the TTM figure through Mar 2026 stood at $1.1 million (down 57.07% YoY), while the FY2025 annual figure was $1.1 million, down 66.77% from the prior year.
- Interest & Investment Income climbed to $486000.0 in Q1 2026 per SPRB's latest filing, from -$40000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.2 million in Q4 2022 and bottomed at -$152000.0 in Q2 2022.
- Historically, Interest & Investment Income has averaged $460529.4 across 5 years, with a median of $329000.0 in 2025.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 18933.33% — and 2025, when it tumbled 107.01%.
- Spruce Biosciences' Interest & Investment Income stood at $2.2 million in 2022, then plunged by 99.86% to $3000.0 in 2023, then jumped by 18933.33% to $571000.0 in 2024, then sank by 107.01% to -$40000.0 in 2025, then surged by 1315.0% to $486000.0 in 2026.
- Business Quant data shows SPRB's Interest & Investment Income at $486000.0 in Q1 2026, -$40000.0 in Q4 2025, and $36000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 765,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 765,000.00 |
| Mar 31, 2026 | 486,000.00 |
| Dec 31, 2025 | -40,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 654,000.00 |
| Mar 31, 2025 | 329,000.00 |
| Dec 31, 2024 | 571,000.00 |
| Sep 30, 2024 | 808,000.00 |
| Jun 30, 2024 | 938,000.00 |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 52,000.00 |
| Jun 30, 2023 | 133,000.00 |
| Mar 31, 2023 | 370,000.00 |
| Dec 31, 2022 | 2.21 Mn |
| Sep 30, 2022 | 266,000.00 |
| Jun 30, 2022 | -152,000.00 |
| Mar 31, 2022 | 58,000.00 |
| Dec 31, 2021 | -264,000.00 |
| Sep 30, 2021 | 41,000.00 |